The 6 analysts offering 12-month price forecasts for Phathom Pharmaceuticals Inc have a median target of 58.50, with a high estimate of 75.00 and a low estimate of 48.00. The median estimate represents a +79.50% increase from the last price of 32.59.
The current consensus among 6 polled investment analysts is to Buy stock in Phathom Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.99
Reporting Date Nov 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.